NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NS-23-078 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-023 from the NIH Guide for Grants and Contracts
Notice NOT-RM-23-006 from the NIH Guide for Grants and Contracts
Notice NOT-MD-23-010 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-23-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite applications for an Integration and Coordination Center (ICC) for the Common Fund Data Ecosystem (CFDE) that will help to build internal cohesion within the program. Award(s) made through this FOA will support CFDE by integrating relevant Common Fund (CF) programs within CFDE, coordinating across other CFDE centers, helping CF programs develop data sustainability plans, and ensuring continuous improvement through an annual evaluation program. The awardee(s) will work collaboratively with each other and other participating components of the CFDE to integrate and coordinate activities across the ecosystem. The end products of CFDE will be a thriving ecosystem that enables the research community to reuse CF data and resources for discoveries and new purposes.
Funding Opportunity RFA-AI-23-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research focused on defining the molecular mechanisms by which HIV proteins and/or nucleic acids induce inflammation, immune activation and HIV persistence during viral suppression as well as on developing novel therapeutic strategies to mitigate or eliminate the effects of continued HIV expression.
Notice NOT-AI-23-035 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-016 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-036 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-018 from the NIH Guide for Grants and Contracts
Notice NOT-DK-23-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-23-028 from the NIH Guide for Grants and Contracts. The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.
Notice NOT-CA-23-053 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-139 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. This FOA supports translational research that includes, but is not limited to, preliminary efficacy and/or early preclinical development studies towards discovery and validation of novel molecular entities or biologics as candidate MCMs. In addition to novel agents, new treatment strategies may involve repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement program and/or other related initiatives.
Notice NOT-AT-24-002 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-23-008 from the NIH Guide for Grants and Contracts. This limited competition FOA invites applications for a Bioinformatics Center to serve as part of the Molecular Transducers of Physical Activity Consortium (MoTrPAC; http://commonfund.nih.gov/MolecularTransducers). The overall goals of the Bioinformatics Center are to provide a database and associated tools for storage and integration of clinical physiological and metabolic data along with multiple types of chemical analysis data derived through metabolomics, proteomics, genomics, transcriptomics, or similar technologies. The Bioinformatics Center coordinates implementation of data and ontology-based metadata standards, provides tools for analysis and visualization of data, provides rapid access to accumulated data and tools through the use of cloud-based computing, and leads data analysis of the diverse datasets submitted by other MoTrPAC elements.
Funding Opportunity RFA-RM-23-009 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite applications for Chemical Analysis Sites to serve as part of the Molecular Transducers of Physical Activity Consortium (MoTrPAC; http://commonfund.nih.gov/MolecularTransducers). This is a limited competition FOA and open only to the previously funded grantees of MoTrPAC Chemical Analysis sites through RFA-RM-15-010 and RFA-RM-15-011. Awards made through this FOA will support participation of grantees in the MoTrPAC consortium activities and the continuation of the analysis of tissues collected by the MoTrPAC consortium. Awardees will conduct omics analysis of tissues collected from human participants undergoing a physical activity intervention, generate well curated datasets, contribute that data to a public consortium database, and participate in the data analysis to generate molecular fingerprints of candidate transducers of physical activity.
Funding Opportunity RFA-RM-23-011 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (NOFO) invites applications for a Consortium Coordinating Center (CCC) to serve as part of the Molecular Transducers of Physical Activity Consortia (MoTrPAC). The goals of the CCC are to provide overall coordination of the Consortium, to monitor study protocol implementation, to coordinate the collection and distribution of data and biological samples from MoTrPAC studies, and to contribute to the creation of a resource for future researchers. Only current MoTrPAC clinical coordinating center awardees are eligible to apply. These will be collaborative cooperative agreements and applicants are expected to use the uniform IRB approved MoTrPAC protocol and have research approaches in accordance with DSMB guidance for analysis of clinical trial data.
Funding Opportunity RFA-RM-23-010 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (NOFO) invites applications to complete recruitment and follow-up for the Molecular Transducers of Physical Activity Consortia (MoTrPAC) clinical studies, including finishing mechanistic randomized controlled trials of sedentary adults and children and observational studies of highly active adults and children. Only current MoTrPAC clinical center awardees are eligible to apply. These will be collaborative cooperative agreements and applicants are expected to use the uniform IRB approved protocol and have research approaches in accordance with DSMB guidance for analysis of clinical trial data.
Funding Opportunity RFA-ES-23-008 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT.